| Bioactivity | Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex[1]. |
| Invitro | Tesidolumab (LFG316) possesses a half-life in humans of approximately 9 days. Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885[1]. |
| Name | Tesidolumab |
| CAS | 1531594-08-7 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488. |